FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Colonno

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Co-author Network

Publications

TOP 3
Fiona McPhee; Nicholas A Meanwell; Kathy Mosure; AK Sheaffer; Michael Sinz; Li-Qiang Sun; Fei Yu; Guangzhi Zhai; Diana Barry; Susan Chaniewski; Chaoqun Chen; Richard J Colonno; Paul Falk; Jacques Friborg; Dennis Hernandez; Jay Knipe; Min S Lee; Steven Levine; Paul Scola
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
John F Kadow; Pin-Fang Lin; Marina Mathew; Nicholas A Meanwell; Daniel Morgan; Dawn Parker; Yasutsugu Ueda; Tao Wang; Zhong Yang; Kap-Sun Yeung; Ming Zheng; Juliang Zhu; John A Bender; Chung-Pin Chen; Caly Chien; Richard J Colonno; Timothy P Connolly; Dennis Grasela
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043).
Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Colonno (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Fiona McPhee; Nicholas A Meanwell; Kathy Mosure; AK Sheaffer; Michael Sinz; Li-Qiang Sun; Fei Yu; Guangzhi Zhai; Diana Barry; Susan Chaniewski; Chaoqun Chen; Richard J Colonno; Paul Falk; Jacques Friborg; Dennis Hernandez; Jay Knipe; Min S Lee; Steven Levine; Paul Scola
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
Antimicrobial agents and chemotherapy 2012;56(10):5387-96.
2012: John F Kadow; Pin-Fang Lin; Marina Mathew; Nicholas A Meanwell; Daniel Morgan; Dawn Parker; Yasutsugu Ueda; Tao Wang; Zhong Yang; Kap-Sun Yeung; Ming Zheng; Juliang Zhu; John A Bender; Chung-Pin Chen; Caly Chien; Richard J Colonno; Timothy P Connolly; Dennis Grasela
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043).
Journal of medicinal chemistry 2012;55(5):2048-56.
2010: Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Nature 2010;465(7294):96-100.
2010: Zheng Yang; Lisa Zadjura; Anthony M Marino; Celia D'Arienzo; Jacek Malinowski; Christoph Gesenberg; Pin-Fang Lin; Richard J Colonno; Tao Wang; John F Kadow; Nicholas A Meanwell; Steven B Hansel
Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
Journal of pharmaceutical sciences 2010;99(4):2135-52.
2010: Ann W Walsh; David R Langley; Richard J Colonno; Daniel J Tenney
Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
PloS one 2010;5(2):e9195.
2010: Julie A Lemm; Donald O'Boyle; Mengping Liu; Peter Nower; Richard J Colonno; Milind S Deshpande; Lawrence B Snyder; Scott W Martin; Denis R St Laurent; Michael H Serrano-Wu; Jeffrey L Romine; Nicholas A Meanwell; Min Gao
Identification of hepatitis C virus NS5A inhibitors.
Journal of virology 2010;84(1):482-91.
2009: Tao Wang; Zhiwei Yin; Zhongxing Zhang; John A Bender; Zhong Yang; Graham Johnson; Zheng Yang; Lisa M Zadjura; Celia J D'Arienzo; Dawn DiGiugno Parker; Christophe Gesenberg; Gregory A Yamanaka; Yi-Fei Gong; Hsu-Tso Ho; Hua Fang; Nannan Zhou; Brian V McAuliffe; Betsy J Eggers; Li Fan; Beata Nowicka-Sans; Ira B Dicker; Qi Gao; Richard J Colonno; Pin-Fang Lin; Nicholas A Meanwell; John F Kadow
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.
Journal of medicinal chemistry 2009;52(23):7778-87.
2009: Jie Fang; Michael J Wichroski; Steven M Levine; Carl J Baldick; Charles E Mazzucco; Ann W Walsh; Bernadette K Kienzle; Ronald E Rose; Kevin A Pokornowski; Richard J Colonno; Daniel J Tenney
Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates.
Antimicrobial agents and chemotherapy 2009;53(7):2762-72.
2009: Daniel J Tenney; Ronald E Rose; Carl J Baldick; Kevin A Pokornowski; Betsy J Eggers; Jie Fang; Michael J Wichroski; Dong Xu; Joanna Yang; Richard B Wilber; Richard J Colonno
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.
Hepatology (Baltimore, Md.) 2009;49(5):1503-14.
2009: Nicholas A Meanwell; Owen B Wallace; Haiquan Fang; Henry Wang; MS Deshpande; Tao Wang; Zhiwei Yin; Zhongxing Zhang; Bradley C Pearce; Jennifer James; Kap-Sun Yeung; Zhilei Qiu; J J Kim Wright; Zheng Yang; Lisa Zadjura; Donald L Tweedie; Suresh Yeola; Fang Zhao; Sunanda Ranadive; Brett A Robinson; Yi-Fei Gong; Hwei-Gene Heidi Wang; Timothy P Spicer; Wade S Blair; Pei-Yong Shi; Richard J Colonno; Pin-Fang Lin
Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns.
Bioorganic & medicinal chemistry letters 2009;19(7):1977-81.
2008: Carl J Baldick; Betsy J Eggers; Jie Fang; Steven M Levine; Kevin A Pokornowski; Ronald E Rose; Cheng-Fang Yu; Daniel J Tenney; Richard J Colonno
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
Journal of hepatology 2008;48(6):895-902.
2008: Carl J Baldick; Daniel J Tenney; Charles E Mazzucco; Betsy J Eggers; Ronald E Rose; Kevin A Pokornowski; Cheng F Yu; Richard J Colonno
Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance.
Hepatology (Baltimore, Md.) 2008;47(5):1473-82.
2008: Pin-Fang Lin; Beata Nowicka-Sans; Brian Terry; Sharon Zhang; Chunfu Wang; Li Fan; ira dicker; Volodymyr Gali; Helen Higley; Neil Parkin; Daniel J Tenney; Mark Krystal; Richard J Colonno
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
Antimicrobial agents and chemotherapy 2008;52(5):1759-67.
2008: Darren S Miller; D Boyle; F Feng; Georget Reaiche; Ieva Kotlarski; Richard J Colonno; Allison R Jilbert
Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Virology 2008;373(2):329-41.
2008: Charles E Mazzucco; RK Hamatake; Richard J Colonno; Daniel J Tenney
Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.
Antimicrobial agents and chemotherapy 2008;52(2):598-605.
2007: Robert G Gish; Anna S F Lok; Ting-Tsung Chang; Robert A de Man; Adrian Gadano; Jose Sollano; Kwang-Hyub Han; You-Chen Chao; Shou-Dong Lee; Melissa Harris; Joanna Yang; Richard J Colonno; Helena Brett-Smith
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gastroenterology 2007;133(5):1437-44.
2007: David R Langley; Ann W Walsh; Carl J Baldick; Betsy Eggers; Ronald E Rose; Steven M Levine; A Jayne Kapur; Richard J Colonno; Daniel J Tenney
Inhibition of hepatitis B virus polymerase by entecavir.
Journal of virology 2007;81(8):3992-4001.
2007: Daniel J Tenney; Ronald E Rose; Carl J Baldick; Steven M Levine; Kevin A Pokornowski; Ann W Walsh; Jie Fang; Cheng-Fang Yu; Sharon Zhang; Charles E Mazzucco; Betsy Eggers; Mayla Hsu; Mary Jane Plym; Patricia Poundstone; Joanna Yang; Richard J Colonno
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Antimicrobial agents and chemotherapy 2007;51(3):902-11.
2007: Chunxiao Ying; Richard J Colonno; Erik De Clercq; Johan Neyts
Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir.
Antiviral research 2007;73(3):192-6.
2007: Kuo-Long Yu; Ny Sin; Rita L Civiello; Xiangdong Alan Wang; Keith Combrink; H Belgin Gulgeze; Brian L Venables; J J Kim Wright; Richard A Dalterio; Lisa Zadjura; Anthony Marino; Sandra Dando; Celia D'Arienzo; Kathleen F Kadow; Christopher Cianci; Zhufang Li; Junius Clarke; Eugene V Genovesi; Ivette Medina; Lucinda Lamb; Richard J Colonno; Zheng Yang; Mark Krystal; Nicholas A Meanwell
Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.
Bioorganic & medicinal chemistry letters 2007;17(4):895-901.
2006: Richard J Colonno; Ronald Rose; Carl J Baldick; Steven Levine; Kevin A Pokornowski; Cheng-Fang Yu; Ann Walsh; Jie Fang; Mayla Hsu; Charles E Mazzucco; Betsy Eggers; Sharon Zhang; Mary Jane Plym; Kenneth Klesczewski; Daniel J Tenney
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Hepatology (Baltimore, Md.) 2006;44(6):1656-65.
2006: Morris Sherman; Cihan Yurdaydin; Jose Sollano; Marcelo Silva; Yun-Fan Liaw; Janusz Cianciara; Anna Boron-Kaczmarska; Paul Martin; Zachary Goodman; Richard J Colonno; Anne Cross; Gail Denisky; Bruce Kreter; Robert Hindes
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Gastroenterology 2006;130(7):2039-49.
2006: Michael Giordano; Thomas Kelleher; Richard J Colonno; Adriano Lazzarin; Kathleen Squires
The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2006;35(4):420-5.
2006: Hsu-Tso Ho; Li Fan; Beata Nowicka-Sans; Brian McAuliffe; Chang-Ben Li; Gregory Yamanaka; Nannan Zhou; Hua Fang; ira dicker; Richard A Dalterio; Yi-Fei Gong; Tao Wang; Zhiwei Yin; Yasutsugu Ueda; John Matiskella; John F Kadow; Paul Clapham; James Robinson; Richard J Colonno; Pin-Fang Lin
Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
Journal of virology 2006;80(8):4017-25.
2006: Ching-Lung Lai; Daniel Shouval; Anna S F Lok; Ting-Tsung Chang; Hugo Cheinquer; Zachary Goodman; Deborah DeHertogh; Richard Wilber; Richard C Zink; Anne Cross; Richard J Colonno; Lori Fernandes
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
The New England journal of medicine 2006;354(10):1011-20.
2006: Ting-Tsung Chang; Robert G Gish; Robert de Man; Adrian Gadano; Jose Sollano; You-Chen Chao; Anna S F Lok; Kwang-Hyub Han; Zachary Goodman; Jin Zhu; Anne Cross; Deborah DeHertogh; Richard Wilber; Richard J Colonno; David Apelian
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
The New England journal of medicine 2006;354(10):1001-10.
2005: Zheng Yang; Lisa Zadjura; Celia D'Arienzo; Anthony Marino; Kenneth Santone; Lewis Klunk; Douglas Greene; Pin-Fang Lin; Richard J Colonno; Tao Wang; Nicholas A Meanwell; Steven Hansel
Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Biopharmaceutics & drug disposition 2005;26(9):387-402.
2005: Ronald S Veazey; Per Johan Klasse; Susan M Schader; Qinxue Hu; Thomas J Ketas; Min Lu; Preston A Marx; Jason Dufour; Richard J Colonno; Robin J Shattock; Martin S Springer; John P Moore
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.
Nature 2005;438(7064):99-102.
2005: Ting-Tsung Chang; Robert G Gish; Stephanos J Hadziyannis; Janusz Cianciara; Mario Rizzetto; Eugene R Schiff; Giuseppe Pastore; Bruce R Bacon; Thierry Poynard; Shobha Joshi; Kenneth S Klesczewski; Alexandra Thiry; Ronald E Rose; Richard J Colonno; Robert G Hindes
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
Gastroenterology 2005;129(4):1198-209.
2005: Joseph Yanchunas; David R Langley; Li Tao; Ronald E Rose; Jacques Friborg; Richard J Colonno; Michael Doyle
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Antimicrobial agents and chemotherapy 2005;49(9):3825-32.
2005: Steve Weinheimer; Linda F Discotto; Jacques Friborg; H Yang; Richard J Colonno
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Antimicrobial agents and chemotherapy 2005;49(9):3816-24.
2005: Wendy K Foster; Darren S Miller; Catherine A Scougall; Ieva Kotlarski; Richard J Colonno; Allison R Jilbert
Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
Journal of virology 2005;79(9):5819-32.
2005: Donald R O'Boyle; Peter Nower; Julie A Lemm; Lourdes Valera; Jin-Hua Sun; Karen Rigat; Richard J Colonno; Min Gao
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.
Antimicrobial agents and chemotherapy 2005;49(4):1346-53.
2005: Julie A Lemm; Mengping Liu; Ronald E Rose; Robert Fridell; Donald R O'Boyle Ii; Richard J Colonno; Min Gao
Replication-competent chimeric hepatitis C virus subgenomic replicons.
Intervirology 2005;48(2-3):183-91.
2004: Christopher Cianci; David R Langley; Douglas D Dischino; Yaxiong Sun; Kuo-Long Yu; Anne Stanley; Julia Roach; Zhufang Li; Richard A Dalterio; Richard J Colonno; Nicholas A Meanwell; Mark Krystal
Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(42):15046-51.
2004: Daniel J Tenney; Steven M Levine; Ronald E Rose; Ann W Walsh; Steve Weinheimer; Linda F Discotto; Mary Jane Plym; Kevin A Pokornowski; Cheng-Fang Yu; Peter W Angus; Anna Ayres; Angeline Bartholomeusz; William Sievert; G Thompson; Nadia Warner; Stephen Locarnini; Richard J Colonno
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Antimicrobial agents and chemotherapy 2004;48(9):3498-507.
2004: Christopher Cianci; Eugene V Genovesi; Lucinda Lamb; Ivette Medina; Zheng Yang; Lisa Zadjura; Hyekyung Yang; Celia D'Arienzo; Ny Sin; Kuo-Long Yu; Keith Combrink; Zhufang Li; Richard J Colonno; Nicholas A Meanwell; Junius Clark; Mark Krystal
Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.
Antimicrobial agents and chemotherapy 2004;48(7):2448-54.
2004: Richard J Colonno; Ronald Rose; Colin McLaren; Alexandra Thiry; Neil Parkin; Jacques Friborg
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
The Journal of infectious diseases 2004;189(10):1802-10.
2004: Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley C Pearce; Alan Wang; Rita L Civiello; Stacey Voss; Guangxiang Luo; Kathleen F Kadow; Eugene V Genovesi; Brian L Venables; H Belgin Gulgeze; Ashok K Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard J Colonno; Junius Clark; Nicholas A Meanwell; Mark Krystal
Orally active fusion inhibitor of respiratory syncytial virus.
Antimicrobial agents and chemotherapy 2004;48(2):413-22.
2003: Qi Guo; Hsu-Tso Ho; ira dicker; Li Fan; Nannan Zhou; Jacques Friborg; Tao Wang; Brian V McAuliffe; Hwei-Gene Heidi Wang; Ronald E Rose; Hua Fang; Helen T Scarnati; David R Langley; Nicholas A Meanwell; Ralph Abraham; Richard J Colonno; Pin-Fang Lin
Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
Journal of virology 2003;77(19):10528-36.
2003: Tao Wang; Zhongxing Zhang; Owen B Wallace; Milind Deshpande; Haiquan Fang; Zheng Yang; Lisa Zadjura; Donald L Tweedie; Stella Huang; Fang Zhao; Sunanda Ranadive; Brett S Robinson; Yi-Fei Gong; Keith Ricarrdi; Timothy P Spicer; Carol Deminie; Ronald Rose; Hwei-Gene Heidi Wang; Wade S Blair; Pei-Yong Shi; Pin-Fang Lin; Richard J Colonno; Nicholas A Meanwell
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
Journal of medicinal chemistry 2003;46(20):4236-9.
2003: Pin-Fang Lin; Wade S Blair; Tao Wang; Timothy P Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; Hwei-Gene Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas A Meanwell; Richard J Colonno
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(19):11013-8.
2003: Justin G Julander; Richard J Colonno; Robert W Sidwell; John D Morrey
Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus.
Antiviral research 2003;59(3):155-61.
2003: Wendy K Foster; Darren S Miller; Patricia L Marion; Richard J Colonno; Ieva Kotlarski; Allison R Jilbert
Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
Antimicrobial agents and chemotherapy 2003;47(8):2624-35.
2003: Jin-Hua Sun; Julie A Lemm; Donald R O'Boyle; Jason Racela; Richard J Colonno; Min Gao
Specific inhibition of bovine viral diarrhea virus replicase.
Journal of virology 2003;77(12):6753-60.
2003: Richard J Colonno; Alexandra Thiry; Kay Limoli; Neil Parkin
Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.
Antimicrobial agents and chemotherapy 2003;47(4):1324-33.
2002: S Levine; Dennis Hernandez; Gregory Yamanaka; Sharon Zhang; Ronald Rose; Steve Weinheimer; Richard J Colonno
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Antimicrobial agents and chemotherapy 2002;46(8):2525-32.
2002: Patricia L Marion; Felix H Salazar; Mark A Winters; Richard J Colonno
Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.
Antimicrobial agents and chemotherapy 2002;46(1):82-8.
2001: Richard J Colonno; Eugene V Genovesi; Ivette Medina; Lucinda Lamb; S K Durham; M L Huang; L Corey; Margaret Littlejohn; Stephen Locarnini; B C Tennant; B Rose; JM Clark
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.
The Journal of infectious diseases 2001;184(10):1236-45.
2000: Eugene V Genovesi; Lucinda Lamb; Ivette Medina; D Taylor; M Seifer; SF Innaimo; Richard J Colonno; JM Clark
Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection.
Antiviral research 2000;48(3):197-203.
2000: Yi-Fei Gong; Brett S Robinson; Ronald E Rose; Carol Deminie; Timothy P Spicer; D Stock; Richard J Colonno; Pin-Fang Lin
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
Antimicrobial agents and chemotherapy 2000;44(9):2319-26.
2000: Brett S Robinson; K A Riccardi; Yi-Fei Gong; Qi Guo; D A Stock; Wade S Blair; B J Terry; Carol Deminie; F Djang; Richard J Colonno; Pin-Fang Lin
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
Antimicrobial agents and chemotherapy 2000;44(8):2093-9.
2000: Guangxiang Luo; RK Hamatake; D M Mathis; J Racela; K L Rigat; Julie A Lemm; Richard J Colonno
De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus.
Journal of virology 2000;74(2):851-63.
1999: Christopher Cianci; Kuo-Long Yu; Douglas D Dischino; WE Harte; MS Deshpande; Guangxiang Luo; Richard J Colonno; Nicholas A Meanwell; Mark Krystal
pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion.
Journal of virology 1999;73(3):1785-94.
1999: Pin-Fang Lin; C J González; B Griffith; G Friedland; V Calvez; F Ferchal; Ray F Schinazi; D H Shepp; A B Ashraf; M A Wainberg; V Soriano; J W Mellors; Richard J Colonno
Stavudine resistance: an update on susceptibility following prolonged therapy.
Antiviral therapy 1999;4(1):21-8.
1999: Gregory Yamanaka; T Wilson; SF Innaimo; Gregory S Bisacchi; P Egli; J K Rinehart; Robert Zahler; Richard J Colonno
Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus.
Antimicrobial agents and chemotherapy 1999;43(1):190-3.
1998: Eugene V Genovesi; Lucinda Lamb; Ivette Medina; D Taylor; M Seifer; SF Innaimo; Richard J Colonno; David Standring; JM Clark
Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.
Antimicrobial agents and chemotherapy 1998;42(12):3209-17.
1998: M Seifer; RK Hamatake; Richard J Colonno; David Standring
In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.
Antimicrobial agents and chemotherapy 1998;42(12):3200-8.
1998: Carol Deminie; C M Bechtold; K Riccardi; Ronald E Rose; H Samanta; Pin-Fang Lin; Richard J Colonno
Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy.
AIDS (London, England) 1998;12(1):110-2.
1997: Daniel J Tenney; Gregory Yamanaka; S M Voss; Christopher Cianci; A V Tuomari; AK Sheaffer; M Alam; Richard J Colonno
Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.
Antimicrobial agents and chemotherapy 1997;41(12):2680-5.
1997: Christopher Cianci; Richard J Colonno; Mark Krystal
Differential effect of modified capped RNA substrates on influenza virus transcription.
Virus research 1997;50(1):65-75.
1997: SF Innaimo; M Seifer; Gregory S Bisacchi; David Standring; Robert Zahler; Richard J Colonno
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus.
Antimicrobial agents and chemotherapy 1997;41(7):1444-8.
1997: Guangxiang Luo; Albert Torri; WE Harte; Stephanie Danetz; Christopher Cianci; Lawrence Tiley; S Day; D Mullaney; Kuo-Long Yu; Carl Ouellet; Pierre Dextraze; Nicholas A Meanwell; Richard J Colonno; Mark Krystal
Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus.
Journal of virology 1997;71(5):4062-70.
1996: Guangxiang Luo; Richard J Colonno; Mark Krystal
Characterization of a hemagglutinin-specific inhibitor of influenza A virus.
Virology 1996;226(1):66-76.
1996: B J Robertson; PJ McCann; L Matusick-Kumar; W W Newcomb; J C Brown; Richard J Colonno; Min Gao
Separate functional domains of the herpes simplex virus type 1 protease: evidence for cleavage inside capsids.
Journal of virology 1996;70(7):4317-28.
1996: C A Deminie; C M Bechtold; D Stock; M Alam; F Djang; A H Balch; T C Chou; Mark Prichard; Richard J Colonno; Pin-Fang Lin
Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.
Antimicrobial agents and chemotherapy 1996;40(6):1346-51.
1996: P Chen; P T Cheng; M Alam; B D Beyer; Gregory S Bisacchi; T Dejneka; A J Evans; J A Greytok; Mark Hermsmeier; W G Humphreys; G A Jacobs; O Kocy; Pin-Fang Lin; K A Lis; M A Marella; Denis E Ryono; AK Sheaffer; S H Spergel; C Q Sun; J A Tino; G Vite; Richard J Colonno; Robert Zahler; J C Barrish
Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.
Journal of medicinal chemistry 1996;39(10):1991-2007.
1996: R E Rose; Y F Gong; J A Greytok; C M Bechtold; B J Terry; B S Robinson; M Alam; Richard J Colonno; Pin-Fang Lin
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(4):1648-53.
1996: RK Hamatake; H G Wang; J A Butcher; M Bifano; G Clark; D Hernandez; S Zhang; J Racela; David Standring; Richard J Colonno
Establishment of an in vitro assay to characterize hepatitis C virus NS3-4A protease trans-processing activity.
Intervirology 1996;39(4):249-58.
1996: Pin-Fang Lin; H Samanta; C M Bechtold; C A Deminie; A K Patick; M Alam; K Riccardi; R E Rose; R J White; Richard J Colonno
Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.
Antimicrobial agents and chemotherapy 1996;40(1):133-8.
1995: Gregory Yamanaka; C L DiIanni; Donald R O'Boyle; J Stevens; Steve Weinheimer; I C Deckman; L Matusick-Kumar; Richard J Colonno
Stimulation of the herpes simplex virus type I protease by antichaeotrophic salts.
The Journal of biological chemistry 1995;270(50):30168-72.
1995: AK Sheaffer; W W Hurlburt; J T Stevens; M Bifano; RK Hamatake; Richard J Colonno; Daniel J Tenney
Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein.
Virus research 1995;38(2-3):305-14.
1995: A K Patick; R Rose; J Greytok; C M Bechtold; Mark Hermsmeier; P T Chen; J C Barrish; Robert Zahler; Richard J Colonno; Pin-Fang Lin
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
Journal of virology 1995;69(4):2148-52.
1994: Min Gao; L Matusick-Kumar; W Hurlburt; S F DiTusa; W W Newcomb; J C Brown; PJ McCann; I Deckman; Richard J Colonno
The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth.
Journal of virology 1994;68(6):3702-12.
1994: C L DiIanni; J T Stevens; M Bolgar; Donald R O'Boyle; Steve Weinheimer; Richard J Colonno
Identification of the serine residue at the active site of the herpes simplex virus type 1 protease.
The Journal of biological chemistry 1994;269(17):12672-6.
1994: T D Chung; Christopher Cianci; M Hagen; B Terry; J T Matthews; Mark Krystal; Richard J Colonno
Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(6):2372-6.
1993: M Alam; C M Bechtold; A K Patick; M T Skoog; T G Gant; Richard J Colonno; A I Meyers; H Li; J Trimble; Pin-Fang Lin
Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors.
Antiviral research 1993;22(2-3):131-41.
1993: C L DiIanni; D A Drier; I C Deckman; PJ McCann; F Liu; B Roizman; Richard J Colonno; M G Cordingley
Identification of the herpes simplex virus-1 protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products.
The Journal of biological chemistry 1993;268(3):2048-51.
1992: Jon H Condra; Emilio A Emini; L Gotlib; D J Graham; A J Schlabach; J A Wolfgang; Richard J Colonno; Vinod Sardana
Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors.
Antimicrobial agents and chemotherapy 1992;36(7):1441-6.
1992: D W Lineberger; C R Uncapher; D J Graham; Richard J Colonno
Domains 1 and 2 of ICAM-1 are sufficient to bind human rhinoviruses.
Virus research 1992;24(2):173-86.
1992: Richard J Colonno
Virus receptors: the Achilles' heel of human rhinoviruses.
Advances in experimental medicine and biology 1992;312():61-70.
1991: R B Register; C R Uncapher; A M Naylor; D W Lineberger; Richard J Colonno
Human-murine chimeras of ICAM-1 identify amino acid residues critical for rhinovirus and antibody binding.
Journal of virology 1991;65(12):6589-96.
1991: E A Garber; H T Chute; Jon H Condra; L Gotlib; Richard J Colonno; R G Smith
Avian cells expressing the murine Mx1 protein are resistant to influenza virus infection.
Virology 1991;180(2):754-62.
1991: C R Uncapher; C M DeWitt; Richard J Colonno
The major and minor group receptor families contain all but one human rhinovirus serotype.
Virology 1991;180(2):814-7.
1990: M G Cordingley; P L Callahan; Vinod Sardana; Victor M Garsky; Richard J Colonno
Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro.
The Journal of biological chemistry 1990;265(16):9062-5.
1990: D W Lineberger; D J Graham; Joanne E Tomassini; Richard J Colonno
Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor.
Journal of virology 1990;64(6):2582-7.
1990: Jon H Condra; Vinod Sardana; Joanne E Tomassini; A J Schlabach; Mary-Ellen Davies; D W Lineberger; D J Graham; L Gotlib; Richard J Colonno
Bacterial expression of antibody fragments that block human rhinovirus infection of cultured cells.
The Journal of biological chemistry 1990;265(4):2292-5.
1989: M G Cordingley; R B Register; P L Callahan; Victor M Garsky; Richard J Colonno
Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli.
Journal of virology 1989;63(12):5037-45.
1989: Joanne E Tomassini; D Graham; C M DeWitt; D W Lineberger; J A Rodkey; Richard J Colonno
cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(13):4907-11.
1989: Joanne E Tomassini; T R Maxson; Richard J Colonno
Biochemical characterization of a glycoprotein required for rhinovirus attachment.
The Journal of biological chemistry 1989;264(3):1656-62.
1989: Richard J Colonno; P L Callahan; D M Leippe; R R Rueckert; Joanne E Tomassini
Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments.
Journal of virology 1989;63(1):36-42.
1988: Richard J Colonno; Jon H Condra; S Mizutani; P L Callahan; Mary-Ellen Davies; M A Murcko
Evidence for the direct involvement of the rhinovirus canyon in receptor binding.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(15):5449-53.
1988: G Abraham; Richard J Colonno
Characterization of human rhinoviruses displaced by an anti-receptor monoclonal antibody.
Journal of virology 1988;62(7):2300-6.
1988: W McClements; G Yamanaka; V Garsky; H Perry; S Bacchetti; Richard J Colonno; R B Stein
Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation.
Virology 1988;162(1):270-3.
1986: Joanne E Tomassini; Richard J Colonno
Isolation of a receptor protein involved in attachment of human rhinoviruses.
Journal of virology 1986;58(2):290-5.
1986: Richard J Colonno; P L Callahan; W J Long
Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses.
Journal of virology 1986;57(1):7-12.
1986: B Sherry; A G Mosser; Richard J Colonno; R R Rueckert
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14.
Journal of virology 1986;57(1):246-57.
1985: P L Callahan; S Mizutani; Richard J Colonno
Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(3):732-6.